Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Abbott Laboratories (NYSE:ABT)

19 Dec 2025, 22:06 by Michael Walen · The Markets Daily

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on December 15th, the Representative disclosed that they had bought between $1,001 and $15,000 in Abbott Laboratories stock on November 18th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Spotify Technology (NYSE:SPOT) on 11/26/2025.
Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 11/26/2025.
Purchased $1,001 – $15,000 in shares of First Watch Restaurant Group (NASDAQ:FWRG) on 11/26/2025.
Purchased $1,001 – $15,000 in shares of TKO Group (NYSE:TKO) on 11/26/2025.
Sold $1,001 – $15,000 in shares of RBC Bearings (NYSE:RBC) on 11/24/2025.
Sold $1,001 – $15,000 in shares of Stifel Financial (NYSE:SF) on 11/24/2025.
Purchased $1,001 – $15,000 in shares of Logan Energy (CVE:LGN) on 11/24/2025.
Sold $1,001 – $15,000 in shares of Primoris Services (NASDAQ:PRIM) on 11/24/2025.
Purchased $15,001 – $50,000 in shares of LandBridge (NYSE:LB) on 11/21/2025.
Purchased $50,001 – $100,000 in shares of LandBridge (NYSE:LB) on 11/20/2025.

Abbott Laboratories Stock Up 0.3%

Abbott Laboratories stock traded up $0.33 during mid-day trading on Friday, reaching $125.45. 13,085,473 shares of the company’s stock were exchanged, compared to its average volume of 6,583,735. The company has a fifty day moving average of $126.91 and a 200-day moving average of $130.32. The company has a market cap of $218.13 billion, a P/E ratio of 15.72, a P/E/G ratio of 2.31 and a beta of 0.72. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23.

Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.30. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The business had revenue of $11.37 billion for the quarter, compared to analysts’ expectations of $11.40 billion. During the same period last year, the firm earned $1.21 earnings per share. The company’s revenue for the quarter was up 6.9% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. Sell-side analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend is Thursday, January 15th. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s payout ratio is currently 29.57%.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. AIA Group Ltd grew its position in Abbott Laboratories by 51.5% in the 3rd quarter. AIA Group Ltd now owns 103,474 shares of the healthcare product maker’s stock valued at $13,859,000 after buying an additional 35,180 shares during the last quarter. Farmers National Bank boosted its holdings in shares of Abbott Laboratories by 22.1% in the third quarter. Farmers National Bank now owns 9,192 shares of the healthcare product maker’s stock valued at $1,231,000 after acquiring an additional 1,662 shares in the last quarter. MRP Capital Investments LLC acquired a new position in shares of Abbott Laboratories during the third quarter worth about $101,000. Saranac Partners Ltd purchased a new position in Abbott Laboratories during the third quarter worth about $550,000. Finally, Allworth Financial LP lifted its position in Abbott Laboratories by 2.6% in the third quarter. Allworth Financial LP now owns 266,483 shares of the healthcare product maker’s stock valued at $35,693,000 after purchasing an additional 6,762 shares during the period. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on ABT. Jefferies Financial Group boosted their price objective on Abbott Laboratories from $145.00 to $149.00 and gave the stock a “buy” rating in a research report on Thursday, October 16th. William Blair upgraded shares of Abbott Laboratories to a “strong-buy” rating in a report on Thursday, November 20th. Wells Fargo & Company lifted their price objective on shares of Abbott Laboratories from $142.00 to $146.00 and gave the stock an “overweight” rating in a research report on Thursday, October 16th. Evercore ISI cut their price target on Abbott Laboratories from $144.00 to $142.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 15th. Finally, Benchmark began coverage on Abbott Laboratories in a research report on Friday, October 10th. They set a “buy” rating and a $145.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $147.00.

Get Our Latest Research Report on ABT

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Abbott Laboratories

(Get Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.